Tanvex BioPharma Inc banner

Tanvex BioPharma Inc
TWSE:6541

Watchlist Manager
Tanvex BioPharma Inc Logo
Tanvex BioPharma Inc
TWSE:6541
Watchlist
Price: 44.8 TWD 0.45% Market Closed
Market Cap: NT$11.9B

Intrinsic Value

The intrinsic value of one Tanvex BioPharma Inc stock under the Base Case scenario is hidden TWD. Compared to the current market price of 44.8 TWD, Tanvex BioPharma Inc is hidden .

Tanvex BioPharma Inc Intrinsic Value
HIDDEN
Show

Valuation History
Tanvex BioPharma Inc

Intrinsic Value History
Dive into the past to invest in the future

Tanvex BioPharma Inc looks overvalued. Yet it might still be cheap by its own standards. Some stocks live permanently above intrinsic value; Historical Valuation reveals whether Tanvex BioPharma Inc usually does or if today's premium is unusual.

Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Show Historical Valuation
What is Valuation History?
Ask AI Assistant
What other research platforms think about Tanvex BioPharma Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is Tanvex BioPharma Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Tanvex BioPharma Inc.

Explain Valuation
Alternatives to Tanvex BioPharma Inc

Wall St
Price Targets

Dividends

Tanvex BioPharma Inc
does not pay dividends
Shareholder Yield
Buyback Yield
HIDDEN
Debt Paydown Yield
HIDDEN

Competitive Landscape

What is the Intrinsic Value of one Tanvex BioPharma Inc stock?

The intrinsic value of one Tanvex BioPharma Inc stock under the Base Case scenario is hidden TWD.

Is Tanvex BioPharma Inc stock undervalued or overvalued?

Compared to the current market price of 44.8 TWD, Tanvex BioPharma Inc is hidden .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett